It rose gradually during the dose-escalation phase, peaked around week 24, and then declined at weeks 36 and 48 even though participants continued taking the same dose
Practical checklist for someone considering peptides or GLP1s Document your baseline: weight, strength levels, sleep, bowel habits, mood, and medication history
GLP-1 activation helps reduce appetite, slow digestion, and improve blood sugar regulation
Eligibility typically requires a BMI of 35 kg/m or above (or 3032.5 kg/m with weight-related comorbidities depending on the medication)
The posttreatment selection of patients for the biomarker analyses was thus affected by the timing of followup measurements, reflecting disease progression and patient behavior, limiting the interpretation of the changes in biomarker values
However, rapid weight loss may unmask underlying androgen-related thinning, which may require separate evaluation and management